EM2004G "COVID-19 and Matters of the Heart" (IM GR-041720)

This presentation will address three topical issues regarding the cardiovascular system and COVID-19. First, we will review data that supports the current recommendation that ACE-inhibitors or ARBs should NOT be routinely discontinued in patients with COVID-19. Second, we will review the potential of hydroxychloroquine, a putative yet unproven pharmacological therapy for COVID-19, to prolong the QT interval, a risk factor for Torsade de Pointes. Third, the clinical manifestations, etiology, prognostic value, and potential management of the Acute Covid-19 Cardiovascular Syndrome will be presented. Together, the goal is to provide practitioners information which will help them treat patients with COVID-19, including those who have cardiac complications.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Know that ACE-inhibitors and ARBs should not be stopped routinely in patients with COVID-19 in an attempt to improve clinical outcome.
  • Know of the concern that hydroxychloroquine may prolong the QT interval and predispose to Torsade de Pointes.
  • Know that troponin elevation, consistent with acute myocardial injury, occurs in a sizeable minority of patients with COVID-19, and is a risk factor for adverse outcomes.
  • Know that the acute myocardial injury in COVID-19 may be caused by either myocarditis or a cytokine storm.
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
04/20/2020
Course expires: 
05/22/2020
Cost:
$0.00
Rating: 
0

Photo: Mark Drazner, M.D. Mark Drazner, M.D.
Professor, Department of Internal Medicine
Clinical Chief of Cardiology
James M. Wooten Chair in Cardiology

Available Credit

  • 1.00 AMA

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome